Radiotherapy of lymphomas.
Fiche publication
Date publication
décembre 2021
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine
Tous les auteurs :
Balosso J, Missohou F, Antoni D, Hennequin C, Mahé MA, Simon L, Demoor-Goldschmidt C
Lien Pubmed
Résumé
Radiotherapy for Hodgkin lymphomas has evolved a lot over time, but still plays an important role, almost always in addition to chemotherapy, for the management of the early stages. The major objective is to preserve the quality of life of patients who will be cured from this disease in the vast majority of cases. Also, the personalization of the indications for the purpose of de-escalating toxicity is very refined and is essentially based on the pre- and pertherapeutic assessment by FDG-PET. The indications for radiotherapy are more limited for non-Hodgkin lymphomas, but the same principles are found, regardless of the histological type. We present the update of the recommendations of the French society of oncological radiotherapy for radiotherapy of lymphomas, which remains a very evolving field in terms of therapeutic strategy and evaluation.
Mots clés
French society for radiation oncology, Guidelines, Hodgkin lymphoma, Lymphome hodgkinien, Lymphomes non hodgkiniens, Non-Hodgkin lymphoma, Radiation therapy, Radiothérapie, Recommandations, Société française de radiothérapie oncologique
Référence
Cancer Radiother. 2021 Dec 21;: